Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphangioma × Alpelisib × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 22 Hereditary Sensory and Autonomic Neuropathies 5 Neoplasms 3 Recurrence 2 Ovarian Neoplasms 2 Multiple Endocrine Neoplasia Type 1 2 Head and Neck Neoplasms 2 Advanced Breast Cancer 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1 Squamous Cell Carcinoma of Head and Neck 1 Pre-menopausal Breast Cancer 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 Kidney Neoplasms 1 Hyperglycemia 1 HER2-positive Metastatic Breast Cancer 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Advanced or Metastatic ER+ Breast Cancer 1 Advanced and Selected Solid Tumors 1 Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1 Advanced Solid Tumor 1 Advanced HER2+Breast Cancer 1 Acrocephalosyndactylia 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948943 2026-02-13

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡